Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-SAPP: Pimavanserin vs Quetiapine for Parkinson's Disease Psychosis
NCT04373317Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) comparing Pimavanserin 34mg with Quetiapine (2 arms). Primary endpoint: Clinical Global Impression-Improvement for Psychosis at 8 weeks. Started Oct 2022; status: recruiting.
02
Drugs
pimavanserinquetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04373317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373317.